Skip to content

Commit

Permalink
a
Browse files Browse the repository at this point in the history
  • Loading branch information
@jfkonecn
jfkonecn committed Feb 25, 2025
1 parent 66f69d6 commit 06feb43
Show file tree
Hide file tree
Showing 2 changed files with 12 additions and 12 deletions.
10 changes: 5 additions & 5 deletions src/main/webapp/app/pages/newsPage/code-generated/NewsContent02262025.tsx
View file
Original file line number Diff line number Diff line change
Expand Up @@ -46,7 +46,7 @@ export default function NewsContent02262025() {
<td>
<em>Drug(s) promoted in OncoKB™:</em>
<br />
Erdafitnib (Level 2, previously Level 4)
Erdafitinib (Level 2, previously Level 4)
<br />
<br />
<em>Drug(s) remaining in OncoKB™:</em>
Expand All @@ -72,7 +72,7 @@ export default function NewsContent02262025() {
<td>
<em>Drug(s) promoted in OncoKB™:</em>
<br />
Erdafitnib (Level 2, previously Level 4)
Erdafitinib (Level 2, previously Level 4)
<br />
<br />
<em>Drug(s) remaining in OncoKB™:</em>
Expand All @@ -98,7 +98,7 @@ export default function NewsContent02262025() {
<td>
<em>Drug(s) promoted in OncoKB™:</em>
<br />
Erdafitnib (Level 2, previously Level 4)
Erdafitinib (Level 2, previously Level 4)
<br />
<br />
<em>Drug(s) remaining in OncoKB™:</em>
Expand All @@ -125,7 +125,7 @@ export default function NewsContent02262025() {
<td>
<em>Drug(s) promoted in OncoKB™:</em>
<br />
Erdafitnib (Level 2, previously Level 4)
Erdafitinib (Level 2, previously Level 4)
<br />
<br />
<em>Drug(s) remaining in OncoKB™:</em>
Expand Down Expand Up @@ -159,7 +159,7 @@ export default function NewsContent02262025() {
<th>Mutation</th>
<th>Cancer Type</th>
<th>Level-Associated Drug(s) in OncoKB™</th>
<th>Drug(s) Added to OncoKBTM</th>
<th>Drug(s) Added to OncoKB™</th>
<th>Evidence</th>
</tr>
</thead>
Expand Down
14 changes: 7 additions & 7 deletions src/main/webapp/app/pages/newsPage/markdown/NewsContent02262025.md
View file
Original file line number Diff line number Diff line change
@@ -1,16 +1,16 @@
- Update to our [FDA-Approved Oncology](https://beta.oncokb.org/oncology-therapies) Therapies page
- Updated Therapeutic Implications - Promotion of tumor type-specific level of evidence for an alteration

| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence |
| :---- | :------------------ | :------------------------- | :---------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- |
| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitnib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| Gene | Mutation | Cancer Type | Level-associated Drug(s) in OncoKB™ | Previous Level | Updated Level | Evidence |
| :---- | :------------------ | :------------------------- | :----------------------------------------------------------------------------------------------------------------------------------------------------------------- | :------------- | :------------ | :--------------------------------------------------------------------------------------------------------------------------- |
| FGFR1 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR2 | Fusions | Pancreatic Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Pancreatic Cancer NCCN Guidelines V2.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR2 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib, Lirafugratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |
| FGFR3 | Oncogenic Mutations | Non-Small Cell Lung Cancer | _Drug(s) promoted in OncoKB™:_<br/>Erdafitinib (Level 2, previously Level 4\)<br/><br/>_Drug(s) remaining in OncoKB™:_<br/>Fexagratinib (Level 4\) | 4 | 2 | Inclusion in Non-Small Cell Lung Cancer NCCN Guidelines V3.2025; PMID: [37541273](https://pubmed.ncbi.nlm.nih.gov/37541273/) |

- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene | Mutation | Cancer Type | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKBTM | Evidence |
| Level | Gene | Mutation | Cancer Type | Level-Associated Drug(s) in OncoKB™ | Drug(s) Added to OncoKB™ | Evidence |
| :---- | :--- | :------- | :---------------- | :---------------------------------- | :---------------------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 1 | BRAF | V600E | Colorectal Cancer | Encorafenib \+ Cetuximab (Level 1\) | Encorafenib \+ Cetuximab \+ FOLFOX Regimen (Level 1\) | [FDA approval of encorafenib with cetuximab and mFOLFOX6](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-encorafenib-cetuximab-and-mfolfox6-metastatic-colorectal-cancer-braf); PMID: [39863775](https://pubmed.ncbi.nlm.nih.gov/39863775/) |

Expand Down

0 comments on commit 06feb43

Please sign in to comment.